Covid19 vaccine trials and Updates

Dr. Hesham Farouk
Specialist Pediatrician
Aster Discovery Gardens& Arabian Ranches
On Aug 11, 2020, Russia became the first country in the world to approve a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine, which is based on two adenovirus vectors, was developed by the Gamaleya National Center of Epidemiology and Microbiology (Moscow, Russia). Its approval was announced by President Vladimir Putin. “I know [the vaccine] works quite effectively, helps to develop strong immunity, and has gone through all the necessary tests”, declared Putin at a cabinet meeting. Nonetheless, there are widespread concerns that the approval is premature. At the time of approval, the vaccine had not even started phase 3 trials, nor had any results on the earlier stage trials been published.
Since then, the phase 1/2 results have been published in The Lancet. The vaccine induced a strong immune response in all 76 participants. Presumably these results were available to the Russian Ministry of Health. For regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency, however, data on immune response alone would not generally be an adequate basis for approving a vaccine. “Immune response might not be directly proportional to the degree of protection—you can only find this out in large-scale trials”, explains Peter Openshaw, professor of experimental medicine at Imperial College London (London, UK).

Sputnik V Vaccine Description

The Russian COVID-19 vaccine Sputnik V is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

And, is a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated. Adenovirus is used as a “container” to deliver the coronavirus gene to cells, start the synthesis of the envelope proteins of the new coronavirus “introducing” the immune system to a potential enemy.


Chinese vaccine against Covid19:


In June 2020, the UAE commenced phase-III of clinical trial of inactivated COVID-19 vaccine. The clinical trial process is usually divided in three phases. Phase-I mainly looks into the safety of the vaccine. Phase-II evaluates the immunogenicity and explores the immunisation process in a limited number of individuals. Phase-III considers the safety and effectiveness of the vaccine in a larger population sample. If a vaccine is confirmed to be safe and effective throughout the entire clinical trial process, the test is considered successful, and the vaccine enters the large-scale manufacturing phase.


The inactivated COVID-19 vaccine passed phases I and II of clinical trials without showing any serious adverse reactions. All volunteers of the clinical trials generated antibodies after two doses in 28 days.


Sinopharm China National Biotec Group (CNBG), a Chinese pharmaceutical company and Group 42 (G42), an artificial intelligence and cloud computing company based in Abu Dhabi signed a clinical cooperation agreement. G42 will lead the clinical trial operations in the UAE under the supervision of Department of Health – Abu Dhabi. A safe and effective vaccine could enter the market by the end of 2020 or early 2021 and relieve mankind of COVID-19.

COVID-19 Vaccine and Therapeutic Drugs Tracker